NEW YORK (GenomeWeb News) – Med Fusion today said that it has inked a validation and market development pact with Theranostics Health aimed at validating the clinical utility of Theranostics Health's personalized medicine assays.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.